A Double-blind, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to Investigate the Efficacy, Tolerability, and Safety of Different Dosing Regimens of AZD8848 Administered Intranasally to Seasonal Allergic Rhinitis Patients Out of Pollen Season in a Nasal Allergen Challenge Model.
Phase of Trial: Phase II
Latest Information Update: 25 Jan 2016
At a glance
- Drugs DSP 3025 (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 23 May 2012 Results presented at the 108th International Conference of the American Thoracic Society.
- 19 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Dec 2010 Planned End Date changed from 1 Mar 2012 to 1 Jan 2012 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History